Numerous RIPK1 inhibitors are currently in clinical trials for inflammatory diseases, including AD (NCT03757325) and ALS (NCT03757351, NCT05237284) [49, 50, 191–193]. This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.